Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV screening

This article was originally published in The Gray Sheet

Executive Summary

In a Sept. 9 1memo, CMS proposes to extend national coverage to lab-based immunoassay and rapid antibody assay screening for HIV in certain high-risk individuals, per U.S. Preventive Service Task Force guidelines. The agency opened its analysis for HIV screening on March 13, marking the first time CMS has initiated a national coverage determination for a screening tool since Congress granted it authority to add coverage for certain preventative services without the need for case-by-case congressional approval (2"The Gray Sheet" March 30, 2009). A final decision is expected by Dec. 8
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT027908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel